Navigation Links
New way discovered to predict which breast cancer patients should be treated with anthracyclines
Date:3/25/2010

Barcelona, Spain: An international team of researchers has discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics*.

The research, presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Thursday), is important because, until now, there was conflicting evidence about the best way of predicting response to anthracyclines and it was unclear whether any of the known biomarkers, such as the genes HER2 and TOP2A, were accurate indicators of response to these drugs.

By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines.

After adjusting for additional factors relating to the tumour and its treatment, the researchers found that if patients with CEP17 were treated with anthracyclines, they were approximately two-thirds more likely to survive and to survive without a recurrence of cancer than those who did not receive anthracyclines (recurrence free survival was 67% and overall survival was 63%).

John Bartlett, Professor of Molecular Pathology at the University of Edinburgh (Edinburgh, UK), said: "Our aim was to identify patients for whom anthracyclines provided benefit in terms of disease control and increased survival, and to seek to ensure that future treatment was targeted to this group. Our finding that patients whose tumours have the CEP17 abnormality are more likely to respond to anthracyclines is entirely novel. Subject to confirmation, this suggests that only those patients with CEP17 tumours should receive anthracyclines, thereby enabling other patients who do not have the CEP17 abnormality to avoid a toxic treatment that will not be effective."

CEP17 is on the same chromosome as two other genes known to be involved in breast cancer, HER2 and TOP2A, but the researchers did not find any significant associations between them and response to anthracycline treatment.

The discovery may open the way not only for clinicians to give anthracycline treatment to patients who will benefit the most from it, but also for biochemists to research the mechanisms involved in CEP17 and to design new drugs to target these pathways.

Prof Bartlett said: "We need to understand what CEP17 is telling us about the behaviour of breast cancer cells. It works as a biomarker for predicting response to anthracyclines, but we don't know why it works. So our next step is to discover this and to try to make the cancers that don't have the marker behave like the ones that do, so that they will respond to anthracyclines."

CEP17 is detected by a common and straightforward test (fluorescent in situ hybridisation or FISH), which is carried out routinely in breast cancer patients; it is used to test for the HER2 gene to see whether the women might benefit from the drug Herceptin. Prof Bartlett said that assessment for CEP17 could be easily carried out in the same FISH analysis as for HER2.

He concluded: "This is the largest study of its kind, with consistent results across multiple trials, and it provides a unifying hypothesis for previous conflicting data."


'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related biology news :

1. New, more direct pathways from outside the cell-to-cell nuclei discovered
2. New continent and species discovered in Atlantic study
3. Ancient organisms discovered in Canadian gold mine
4. New golden frog discovered in remote region of Colombia
5. Antioxidant to retard wrinkles discovered by Hebrew University researcher
6. One species entire genome discovered inside anothers
7. New molecules discovered that block cancer cells from modifying cell DNA
8. Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues
9. How schizophrenia develops: Major clues discovered
10. New 150 million-year-old crab species discovered
11. Worlds hottest chile pepper discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... N.Y. , Aug. 23, 2017  The general public,s help is ... human microbiome—the bacteria that live in and on the human body –and ... The ... in the human microbiome, starting with the gut. The project's goal is ... disease. Photo credit: IBM ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 ... a leader in dairy research, today announced a new ... help reduce the chances that the global milk supply ... this dairy project, Cornell University has become the newest ... Food Supply Chain, a food safety initiative that includes ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
Breaking Biology Technology: